Tesamorelin / Ipamorelin Blend

Description

The Tesamorelin / Ipamorelin blend is one of the cleaner examples of pharmacological pathway pairing in research peptide protocols. Two compounds, two receptors, one endpoint: GH release. But the pathways from receptor to endpoint are different enough — Tesamorelin through GHRH-R and Gs signaling, Ipamorelin through GHSR-1a and Gq signaling — that co-administration isolates pathway contribution rather than duplicating it. That is the structural rationale most dual-pathway research protocols depend on.

Proposed Mechanism

Tesamorelin is a 44-amino-acid GHRH analogue, modified with an N-terminal hexenoyl group that blocks the DPP-IV cleavage that destroys native GHRH within minutes. It binds the GHRH receptor on anterior pituitary somatotropes and triggers the canonical Gs-adenylyl cyclase-PKA cascade. Ipamorelin is a selective pentapeptide agonist of GHSR-1a — the ghrelin receptor — on the same somatotrope population. GHSR-1a signals through Gq and phospholipase C rather than Gs and adenylyl cyclase, which is what makes the dual-pathway design meaningful. Raun et al. (1998, European Journal of Endocrinology) characterized Ipamorelin’s receptor selectivity, reporting that the compound does not measurably elevate ACTH, cortisol, or prolactin — a clean profile that distinguishes it from earlier GH secretagogues.

Research Literature

Ferdinandi et al. (2007, Basic & Clinical Pharmacology & Toxicology) is the Tesamorelin pharmacokinetic paper. Raun et al. (1998) is the Ipamorelin discovery and selectivity paper. Alba et al. (2006) is the relevant combination-protocol reference, examining dual-pathway GH-axis stimulation in research contexts. Researchers using this blend reference the component papers for compound-specific mechanism work and Alba for the pairing rationale. The additive-vs-synergistic question (does co-administration produce GH release beyond the sum of the two single-pathway responses?) is the underlying research question that most studies using this blend are actually probing.

Further reading: PubMed references for this compound.

Research Applications

Used in dual-pathway somatotropic axis research, GHRH and GHSR-1a signaling comparison studies, and protocols examining the complementarity of Gs-coupled (GHRH) and Gq-coupled (GHSR-1a) GH-release mechanisms. Frequently the reference blend for researchers isolating synergistic from additive receptor-pathway effects.

Supplied strictly for laboratory research use. Not for human or veterinary use.

Reconstitution

Supplied as a lyophilized powder. Reconstitute with bacteriostatic water prior to use. Use the Peptigo reconstitution calculator for guidance on volume and concentration.

Storage

• Unopened: room temperature up to 30 days during transit; refrigerate at 2-8°C long-term.
• Reconstituted: refrigerate at 2-8°C; stable 4-6 weeks. Protect from light.

Quality Verification

Every batch is independently tested by Janoshik Analytical. Certificates of Analysis include HPLC-UV purity, LC-MS identity confirmation, LAL bacterial endotoxin quantification, and USP <71> sterility testing.

Not a drug, supplement, or cosmetic. For in vitro research use only. Not for human consumption.

Frequently Asked Questions

Is this product legal to purchase in Canada for research use?

Peptigo supplies all products strictly for laboratory and in vitro research use. The compound is not a drug, supplement, or cosmetic, and is not sold for human or veterinary use. Researchers purchasing for their own laboratory work, university research programs, or independent in vitro protocols are the intended customer base. Health Canada’s April 2026 advisory specifically addresses unauthorized injectable peptide use; the research-use framing of this product is independent of that consumer-use category.

How is purity verified, and where can I see the Certificate of Analysis?

Every batch is tested independently by Janoshik Analytical, an accredited third-party laboratory. The standard testing panel includes HPLC-UV purity verification, LC-MS identity confirmation, LAL bacterial endotoxin quantification, and USP sterility testing. The Certificate of Analysis for each batch is available on the product page after purchase, and the testing methodology is detailed on the Lab Testing reference page.

What is the standard reconstitution and storage protocol for laboratory use?

The compound is supplied as a lyophilized powder. The standard diluent for reconstitution in research protocols is bacteriostatic water (0.9% benzyl alcohol). The Peptigo reconstitution calculator handles the volume-and-concentration arithmetic for a given target research dose. Unopened lyophilized peptide is stable at room temperature for up to 30 days during transit and should be refrigerated at 2-8°C for long-term storage. Reconstituted peptide should be refrigerated at 2-8°C and is typically functional for 4-6 weeks; protect from light.